Centers for Medicare & Medicaid Services regulators have finalized a hard ceiling on what a 2027 Medicare Part D drug plan may charge during the initial coverage phase, the stretch of the year before catastrophic protection takes over. A generic prescription may cost no more than $20 and a preferred brand or brand-name drug no more than $47 under any benefit design CMS will accept into next year’s bidding cycle. Five other drug categories carry their own separate maximums, from $100 for non-preferred and injectable drugs down to $0 for a recommended vaccine. The number in a plan’s bid is a ceiling regulators will approve, not a price every enrollee is guaranteed to pay.
The Ceiling a 2027 Bid Cannot Cross
The maximums sit inside the Contract Year 2027 Part D Bidding Instructions, the technical document CMS uses to accept or reject an insurer’s annual benefit design before it can be sold during Medicare’s fall open enrollment. Every insurer submits a proposed copay for each drug tier as part of that design, and CMS checks the proposal tier by tier against a published maximum rather than against a single blended number. That tier-by-tier structure is why a generic and a preferred brand, dispensed at the same pharmacy counter, can carry copays that sit more than double apart under the exact same plan.
For the initial coverage phase, the finalized instructions cap a generic copay at $20 and a preferred brand or brand-name copay at $47, the two figures a 2027 plan cannot cross no matter how the rest of its formulary is built. A ceiling is not a bill: insurers commonly price their cheapest tiers below the maximum to compete for enrollment during the fall shopping season, when a low generic copay is an easy number to advertise against a rival plan’s pricing. That competitive pressure tends to loosen at the brand tier, where list prices are already high enough that a plan has more room to charge close to the maximum without losing a shopper who mainly compares the generic-tier number.
Where the help is written down: The programs that lower Medicare costs each run on a different form and a different office, and no single notice lists them together. See the state cost-help packs in The Medicare Cost & Coverage Protection Kit.
Non-Preferred and Injectable Drugs Share a $100 Ceiling, With a Guardrail Against Gaming
Two tiers further down the same schedule share an identical $100 maximum: non-preferred drugs, the catch-all category for brand and generic medications a plan did not place on a lower tier, and injectable drugs, billed separately because they typically require administration rather than a simple pharmacy pickup. Both figures sit five times above the generic ceiling, marking where the same finalized instructions accept that a plan’s cost exposure justifies a steeper copay than anything on the first two tiers.
The bidding instructions attach a separate rule to the non-preferred tier specifically: a plan may not fill more than 25 percent of that tier’s drug list with generic drugs. Without that limit, an insurer could shift inexpensive generics off the $20 tier and onto the $100 tier, collecting a far larger copay on medications that cost the plan very little to cover in the first place. The 25 percent cap is a narrow technical rule, but it is the mechanism that keeps the non-preferred tier reserved for drugs that are genuinely costlier rather than a pricing shortcut built on reclassification.
A Lower Ceiling for Chronic Care, a Zero-Dollar Floor for Vaccines
Two categories run below the generic ceiling rather than above it. Drugs the instructions designate as select care or diabetic medications are capped at $11, a maximum reserved for treatments tied to conditions CMS has decided should carry the lowest realistic cost barrier to keep enrollees filling a prescription on schedule. A missed diabetes medication tends to produce far more expensive medical costs down the line than the drug itself would have cost the plan, the standard actuarial argument for pricing that tier below even the $20 generic ceiling most enrollees will see on other prescriptions.
Vaccines carry no ceiling at all: CMS requires $0 cost sharing, a rule that traces to the Inflation Reduction Act’s redesign of the Part D benefit rather than to the 2027 bidding cycle specifically. Adult vaccines recommended by the Advisory Committee on Immunization Practices continue to carry no copay and no deductible under that redesign, according to a 2027 policy summary from actuarial consultancy Axene Health Partners, which tracks the same annual bid cycle CMS regulators use to evaluate every 2027 plan submission.
The Threshold That Decides Who Gets a Pharmacist’s Medication Review
The same finalized instructions move a separate number that has nothing to do with copays: the cost threshold that qualifies a beneficiary for a plan’s medication therapy management program. For 2027, that threshold rises to $1,340, up from $1,276 in 2026, based on the average annual cost of eight generic drugs, a benchmark CMS recalculates every year to keep pace with drug pricing rather than holding it fixed while other Part D costs continue to climb.
Medication therapy management gives a beneficiary who crosses that dollar threshold, while also taking multiple drugs for chronic conditions, a pharmacist-led review of everything in their regimen, at no separate charge beyond what the plan already collects on the covered drugs themselves. Because the threshold is a cost total rather than a drug count, a beneficiary can qualify by filling a small number of expensive brand-name prescriptions or a larger number of cheaper ones, provided the combined annual total clears $1,340 under the 2027 calculation.
The bidding instructions arrived within a broader 2027 payment cycle: CMS finalized them on February 6, 2026, then followed in April with the broader Medicare Advantage and Part D rate announcement that confirmed the year’s payment policies before the same bid-submission deadline every 2027 plan sponsor had to meet. Every ceiling inside that February document — the copay maximums, the 25 percent composition limit, the $1,340 threshold — functions as an outer boundary CMS checks a bid against, not a promise of what any single 2027 Part D plan will actually charge once a prescription reaches the counter.
Reading a Copay Schedule Against a Prescription List
The ceilings in CMS’s bidding instructions set the outer edge of what a 2027 plan may charge on each drug tier, but they say nothing about the separate programs that can push an actual cost below any of those figures for a given enrollee. Extra Help, a state pharmaceutical assistance program, and a manufacturer copay card each run through a different office and a different form, and a plan’s own paperwork rarely lists more than one of them side by side.
The Medicare Cost & Coverage Protection Kit is a 10-page kit built around 51 state Medicare cost-help packs and a medication and cost tracker for weighing a plan’s tier ceilings against what a specific prescription list actually costs.
Look up a state’s cost-help programs in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
